Baxter/NAVA
Executive Summary
Deadline for Baxter acquisition of North American Vaccine extended to June 30 from May 31 under a modified share exchange agreement, because certain conditions have yet to be met. Original agreement hinged on approval of NAVA's group C meningococcal conjugate vaccine NeisVac-C by April 1 (1"The Pink Sheet" Nov. 22, 1999, p. 17). Shareholders will now receive $6.73 per share as opposed to $7 per share